P-LLY Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about retatrutide as a potential treatment for adults with obesity or overweight and at least one weight-related comorbidity, potential efficacy and tolerability of retatrutide, and the timeline for future readouts, presentations, and other milestones relating to retatrutide and its clinical trials and reflects Lilly's current beliefs and expectations
Dose exposure: starting weight matters A lighter body has less blood and tissue in which to distribute the same dose, leaving more retatrutide available to reach receptors
While comparisons like "Retatrutide vs tirzepatide" show that Retatrutide may offer enhanced effectiveness, direct treatment trials are still ongoing
Independent analysis Posted reports identify the independent laboratory and the analytical work represented
It takes around 45 half-lives (about 2430 days) to clear
doi: 10.1002/alz.12638 113 QiuCKivipeltoMvon StraussE
